SC
SANA icon

Sculptor Capital’s Sana Biotechnology SANA Stock Holding History

Sculptor Capital’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,400
Closed -$79.2K – 404
2023
Q4 		$79.2K Hold
19,400
– – ﹤0.01% 252
2023
Q3 		$75.1K Hold
19,400
– – ﹤0.01% 258
2023
Q2 		$116K Buy
+19,400
New +$112K ﹤0.01% 255

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sculptor Capital's SANA Position: Q1 2024 in Review

Sculptor Capital sold out of Sana Biotechnology (SANA) in Q1 2024, closing a stake of 19,400 shares — an estimated $79.2K sold.

Sculptor Capital first reported a position in SANA in Q2 2023 and held it in 3 quarters. The position peaked at $116K in Q2 2023. 154 funds tracked by Wall St. Rank hold SANA as of Q1 2024.

  • Sculptor Capital reported no remaining Sana Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Sculptor Capital sold 19,400 Sana Biotechnology shares in Q1 2024, an estimated $79.2K.
  • Sculptor Capital first reported a position in Sana Biotechnology in Q2 2023 and held it in 3 quarters.
  • Sculptor Capital's Sana Biotechnology position peaked at $116K in Q2 2023.
  • 154 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2024.

Based on Sculptor Capital's 13F filing for Q1 2024, filed 15 May 2024.